Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited has announced the completion of enrolment for their Open-Label Extension study, revealing that their drug monepantel significantly extends survival in MND/ALS patients by 91% compared to historical controls. The treatment also slows disease progression, with some patients showing no decline or slight improvement in condition. These promising results are a precursor to the upcoming Phase 2/3 STRIKE study.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
